[Corrigendum] Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancer

Iida,Katsuyuki; Zheng,Rong; Shen,Ruoqian; Nanus,David M.

doi:10.3892/ijo.2024.5694

November-2024 Volume 65 Issue 5

Full Size Image

Cover Legend PDF

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-2024 Volume 65 Issue 5

Full Size Image

Cover Legend PDF

Correction Open Access

[Corrigendum] Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancer

Authors:
- Katsuyuki Iida
- Rong Zheng
- Ruoqian Shen
- David M. Nanus
View Affiliations / Copyright

Affiliations: Genitourinary Oncology Research Laboratory, Department of Medicine, Weill Cornell Medical College and Weill Cornell Cancer Center, New York, NY 10021, USA

Copyright: © Iida et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Article Number: 106
|
Published online on: September 16, 2024

https://doi.org/10.3892/ijo.2024.5694
Expand metrics +

Article

Int J Oncol 41: [Related article:] 1192-1198, 2012; DOI: 10.3892/ijo.2012.1586

Subsequently to the publication of the above article, an interested reader drew to the authors' attention that, for the immunostaining experiments shown in Fig. 3C on p. 1195, the 'NEP' and 'PTX' panels contained overlapping data, such that data which were intended to show the results of differently performed experiments had apparently been derived from the same original source.

Figure 3

AdNEP infection augments paclitaxel induced apoptosis in DU145 cells. (A) Relative viable cell number of cells infected with AdNEP or AdLacZ in combination with paclitaxel. Following infection with AdNEP or AdLacZ at 10 pfu/cell, cells were treated with paclitaxel at 5 or 10 ng/ml, or vehicle for 48 h and counted at 5 days. Combination therapy with AdNEP plus paclitaxel significantly decreased cell viability. (B) Total cell lysates from DU145 cells treated as indicated and described above were separated by SDS-PAGE and immunoblotted with mAbs to caspase-3 and PARP-1. Infection with AdNEP increased caspase-3 and PARP-1 cleavage products compared with paclitaxel treatment of control cells infected with AdLacZ. (C) Representative immunostain of cells treated with AdLacZ or AdNEP plus paclitaxel. (D) Apoptotic index was calculated as the number of positive cells × 100/total number of cells counted under ×400 magnification in 10 randomly selected areas in each sample. a, P<0.01 compared with AdLacZ plus vehicle treated cells. b, P<0.01 compared with AdLacZ plus paclitaxel treated cells.

After re-examining their original data, the authors have realized that the 'PTX' data panel in Fig. 3C had inadvertently been selected incorrectly. The revised and corrected version of Fig. 3, showing the correct data for the 'PTX' data panel in Fig. 3C, is shown on on the next page. The authors are grateful to the Editor of International Journal of Oncology for allowing them this opportunity to publish this Corrigendum, and all the authors agree with its publication. Furthermore, the authors apologize to the readership for any inconvenience caused.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

[Corrigendum] Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancer

This article is mentioned in:

Article

Figure 3

Related Articles